Vimarsana
Biggest News Aggregation in the World

Page 9 - Crossover Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Crossover Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Crossover Management Today - Breaking & Trending Today

CymaBay Therapeutics (NASDAQ:CBAY) Stock Price Passes Above 50 Day Moving Average of $2.28 - Vimarsana News

CymaBay Therapeutics (NASDAQ:CBAY) Stock Price Passes Above 50 Day Moving Average of $2.28

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Buy" from Brokerages - Vimarsana News

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Buy" from Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) has earned an average recommendation of “Buy” from the eight analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average […]

Insider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Purchases 16,849 Shares of Stock - Vimarsana News

Insider Buying: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Purchases 16,849 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) major shareholder Bros. Advisors Lp Baker bought 16,849 shares of the stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $5.84 per share, for a total transaction of $98,398.16. Following the completion of the acquisition, the insider now owns 4,436,709 […]

The Goldman Sachs Group Lowers Entrada Therapeutics (NASDAQ:TRDA) Price Target to $10.00 - Vimarsana News

The Goldman Sachs Group Lowers Entrada Therapeutics (NASDAQ:TRDA) Price Target to $10.00

Entrada Therapeutics (NASDAQ:TRDA – Get Rating) had its target price cut by equities research analysts at The Goldman Sachs Group from $22.00 to $10.00 in a report released on Tuesday, Stock Target Advisor reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside […]

Akouos (NASDAQ:AKUS) Downgraded to Sell at Zacks Investment Research - Vimarsana News

Akouos (NASDAQ:AKUS) Downgraded to Sell at Zacks Investment Research

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.